                               SEQUENCE LISTING

<110> CHILDREN'S MEDICAL CENTER CORPORATION
 
<120> METHODS RELATED TO BREAKING T CELL EXHAUSTION

<130> 701039-087941-PCT

<140> PCT/US2017/057534
<141> 2017-10-20

<150> 62/410,910
<151> 2016-10-21

<160> 8     

<170> PatentIn version 3.5

<210> 1
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
      primer

<400> 1
gaagaacaag cccgaccaga                                                   20


<210> 2
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
      primer

<400> 2
ccacctgggt cacactcttc                                                   20


<210> 3
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
      primer

<400> 3
tgggctacac tgagcaccag                                                   20


<210> 4
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
      primer

<400> 4
gggtgtcgct gttgaagtca                                                   20


<210> 5
<211> 9
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
      peptide

<400> 5
Lys Ala Val Tyr Asn Phe Ala Thr Met 
1               5                   


<210> 6
<211> 11
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
      peptide

<400> 6
Ser Gly Val Glu Asn Pro Gly Gly Tyr Cys Leu 
1               5                   10      


<210> 7
<211> 9
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
      peptide

<400> 7
Phe Gln Pro Gln Asn Gly Gln Phe Ile 
1               5                   


<210> 8
<211> 20
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
      peptide

<400> 8
Gly Leu Asn Gly Pro Asp Ile Tyr Lys Gly Val Tyr Gln Phe Lys Ser 
1               5                   10                  15      


Val Glu Phe Asp 
            20  


